NASDAQ: JANX - Janux Therapeutics, Inc.

Rentabilité sur six mois: -41.41%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Janux Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.

plus de détails
The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2021-06-11
ISIN US47103J1051
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.januxrx.com
Цена ао 30.12
Changement de prix par jour: 0% (28.95)
Changement de prix par semaine: +21.69% (23.79)
Changement de prix par mois: -5.64% (30.68)
Changement de prix sur 3 mois: -36.16% (45.35)
Changement de prix sur six mois: -41.41% (49.41)
Changement de prix par an: -42.73% (50.55)
Evolution du prix sur 3 ans: +105.9% (14.06)
Evolution des prix depuis le début de l'année: -47.49% (55.13)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 271.8 1
P/BV 2.81 6
P/E 0 0
EV/EBITDA -24.99 0
Total: 1.5

Efficacité

Nom Signification Grade
ROA, % -9.57 0
ROE, % -10.09 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.2329 10
Total: 8.4

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 2686.32 10
Rentabilité Ebitda, % 1397.68 10
Rentabilité EPS, % 204.67 10
Total: 10
Plus de détails

Établissements Volume Partager, %
RA Capital Management, L.P. 9165652 17.74
FMR, LLC 4671213 9.04
BVF Inc. 4579818 8.87
Orbimed Advisors LLC. 3317927 6.42
Citadel Advisors Llc 3120205 6.04
Janus Henderson Group PLC 1931477 3.74
Blackrock Inc. 1762101 3.41
Adage Capital Partners GP L.L.C. 1355475 2.62
Vanguard Group Inc 979483 1.9
Geode Capital Management, LLC 408190 0.79

ETFPartager, %Rentabilité pour l'année, %Dividendes, %
Future Tech ETF 0.25252 426.34 0.8416
Principal Healthcare Innovators ETF 0.25252 618.5 0.8416
0.25522.420.84



Superviseur Titre d'emploi Paiement Année de naissance
Dr. David Alan Campbell Ph.D. President, CEO & Director 1.04M 1960 (65 années)
Mr. Byron Robinson J.D., Ph.D. Chief Strategy Officer 723k 1965 (60 années)
Mr. Charles M. Winter Chief Technical Officer 590.4k 1969 (56 années)
Mr. James Pennington General Counsel N/A
Ms. Brenda Van Vreeswyk Head of Human Resources N/A
Mr. Andy Hollman Meyer Chief Business Officer N/A 1984 (41 année)
Dr. Tommy Diraimondo Ph.D. Chief Scientific Officer N/A 1986 (39 années)
Mr. Matt Whitmire Vice President of Finance
Ms. Maria Dobek Principal Accounting Officer & VP of Accounting 1989 (36 années)

Adresse: United States, La Jolla. CA, 11099 North Torrey Pines Road - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.januxrx.com